# Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

> **NCT03223597** · — · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 300 (actual)

## Conditions studied

- Prostate Cancer Metastatic
- Bone Metastases

## Interventions

- **DRUG:** Radium-223 dichloride

## Key facts

- **NCT ID:** NCT03223597
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-17
- **Primary completion:** 2015-02-01
- **Final completion:** 2018-03-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03223597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03223597, "Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03223597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*